Rosetta Genomics Receives Full Settlement Payment from Sanra Laboratories

  Rosetta Genomics Receives Full Settlement Payment from Sanra Laboratories

PR Newswire

PHILADELPHIA and REHOVOT, Israel, May 10, 2013

PHILADELPHIA and REHOVOT, Israel, May 10, 2013 /PRNewswire/ --Rosetta
Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of
microRNA-based molecular diagnostics, announces receipt of $625,000 as payment
in full from the negotiated settlement announced on April 18, 2013 with Sanra
Laboratories (Sanra) in connection with the Company's sale to Sanra of Parkway
Clinical Laboratories (Parkway).

On July 22, 2008, through Rosetta Genomics Inc., the Company purchased all of
the shares of Parkway Clinical Laboratories, Inc., a privately held
Pennsylvania corporation owning a CLIA-certified laboratory. With its CLIA
certification, Parkway helped Rosetta Genomics to obtain CLIA certification
for its laboratory in Philadelphia. Parkway remained an indirect, wholly
owned subsidiary until May 18, 2009, when the Company sold Parkway to Sanra
for up to $2.5 million, to be paid as a fixed percentage from the revenues
over six years.

About miRview^® Testing Services

miRview^® assays are a series of microRNA-based diagnostic testing services
offered by Rosetta Genomics. miRview^® mets² accurately identifies the primary
tumor type in primary and metastatic cancer including cancer of unknown or
uncertain primary (CUP). miRview^® meso diagnoses mesothelioma, a cancer
connected to asbestos exposure. miRview^® lung accurately identifies the four
main subtypes of lung cancer using small amounts of tumor cells. miRview^®
kidney accurately classifies the four most common kidney tumors: clear cell
renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.
miRview^® assays are designed to provide objective diagnostic data; it is the
treating physician's responsibility to diagnose and administer the appropriate
treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000
patients a year may benefit from the miRview^® mets² assay, 60,000 from
miRview^® meso, 65,000 from miRview^® kidney and 226,000 patients from
miRview^® lung. The Company's assays are offered directly by Rosetta Genomics
in the U.S., and through distributors around the world. For more information,
please visit www.mirviewdx.com. Parties interested in ordering the test can
contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based molecular
diagnostics. Founded in 2000, Rosetta's integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic tools.
Rosetta's miRview® testing services are commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan
recognized Rosetta Genomics with the 2012 North American Next Generation
Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations,
plans and prospects, including without limitation, Rosetta's development or
commercialization of molecular diagnostics, the market acceptance of Rosetta's
miRview^®assays,particularly miRview^®mets^2, Rosetta's capitalization of
its microRNA platform, Rosetta's patent positionand Rosetta's development of
personalized medicine products and servicesconstitute forward-looking
statements for the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995. Actual results may differ materially
from those indicated by these forward-looking statements as a result of
various important factors, including those risks more fully discussed in the
"Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year
ended December 31, 2012as filed with the SEC. In addition, any
forward-looking statements represent Rosetta's views only as of the date of
this release and should not be relied upon as representing its views as of any
subsequent date. Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.

Company Contact:
Rosetta Genomics
Ken Berlin, President & CEO
(215) 382-9000, ext. 326
investors@rosettagenomics.com

Investor Contacts:
LHA
Anne Marie Fields
(212) 838-3777
afields@lhai.com
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com



SOURCE Rosetta Genomics Ltd.

Website: http://www.mirviewdx.com
 
Press spacebar to pause and continue. Press esc to stop.